


Lamivudine-¹³C,¹⁵N₂,d₂

Cat. No.:	HY-B0250S1
Molecular Formula:	C ₇ ¹³ CH ₉ D ₂ N ¹⁵ ₂ O ₃ S
Molecular Weight:	234.25
Target:	Isotope-Labeled Compounds; HBV; Reverse Transcriptase; HIV
Pathway:	Others; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Lamivudine-¹³C,¹⁵N₂,d₂ (BCH-189-¹³C,¹⁵N₂,d₂) is a ¹³C, ¹⁵N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase^{[1][2][3][4]}.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. *Hepatology.* 1997 Jul;26(1):216-25.
- [3]. Olaniyan LW, et al. Lamivudine-Induced Liver Injury. *Open Access Maced J Med Sci.* 2015 Dec 15;3(4):545-50.
- [4]. Mdanda S, et al. Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. *Assay Drug Dev Technol.* 2019 Oct;17(7):322-329.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA